Anti-Müllerian hormone and HOMA-IR in different phenotypes of polycystic ovary syndrome on insulin resistance

Year 2023, , 376 - 382, 27.10.2023

Murat Önal , Halime Çalı Öztürk

https://doi.org/10.38053/acmj.1323489

Abstract

Aims: To examine the link between serum anti-mullerian hormone (AMH) levels and homeostatic model assessment of insulin resistance (HOMA-IR) in different phenotypes of polycystic ovary syndrome (PCOS).
Methods: This retrospective study included 120 patients aged 18-30 who visited our polyclinics between June 2021 and December 2022. Patients were divided into four groups based on the Rotterdam criteria for PCOS phenotypes. A control group of 24 individuals was also included. Clinical data, hormonal profiles, and metabolic parameters were obtained from medical records.
Results: There were significant differences in AMH, follicle stimulating hormone (FSH), luteinizing hormone (LH), and high-density lipoprotein (HDL) levels among the PCOS phenotypes and control group. AMH levels were highest in phenotype 1 (oligo/anovulation + hyperandrogenism + polycystic ovaries) and lowest in the control group. FSH were highest in phenotype 4 (oligo/anovulation + polycystic ovaries) and lowest in the control group. LH were highest in phenotype 2 (oligo/anovulation + hyperandrogenism). HOMA-IR was highest in phenotype 1. However, there were no significant differences in AMH or HOMA-IR levels among the PCOS phenotypes.
Conclusion: Our study found hormone level differences among PCOS phenotypes but no significant differences in AMH or HOMA-IR. This suggests AMH may not distinguish between phenotypes and insulin resistance may not differ significantly among phenotypes.

Keywords

PCOS phenotypes, anti-mullerian hormone, insulin resistance, HOMA-IR, biomarkers

References

• Asanidze E, Kristesashvili J, Parunashvili N, Urjumelashvili M, Tsetskhladze Z, Asanidze A. Hyperhomocysteinemia and pregnancy outcomes in women with polycystic ovary syndrome: a case-control study. Int J Reprod Biomed. 2023;21(2):167-174.
• Dokuzeylül Güngör N, Gürbüz T. Pregnancy outcomes of intrauterine insemination in age-matched young women according to serum anti-mullerian hormone levels. JRM. 2021:195-202.
• Bahadur A, Verma N, Mundhra R, et al. Correlation of homeostatic model assessment-insulin resistance, anti-mullerian hormone, and bmi in the characterization of polycystic ovary syndrome. Cureus. 2021;13(6):e16047.
• Gurbuz T, Alanya Tosun S, Cebi A, Gokmen O, Usta M. Investigating fetuin-A and paraoxonase-1 activity as markers in polycystic ovary syndrome based on body mass index: a prospective case-control study. Cureus. 2021;13(10):e18553.
• Chen Y, Deng M, Chen Z, et al. Insulin-like peptide 5 (INSL5) positively correlates with anti-Müllerian hormone (AMH) in women with the polycystic ovary syndrome: a case-control study. J Ovarian Res. 2022;15(1):118.
• Alanya Tosun Ş, Gurbuz T, Cebi A, Tosun A, Gokmen O, Usta M. Association of increased levels of omentin-1 and carotid intima-media thickness with early signs of cardiovascular risk in patients with polycystic ovary syndrome: a prospective case control study. J Obstet Gynaecol Res. 2022;48(1):169-177.
• Dokuzeylül Güngör N, Güngör K, Celik N, Önal M, Madenli AA. Impact of body mass index and vitamin D on serum AMH levels and antral follicle count in PCOS. Eur Rev Med Pharmacol Sci. 2023;27(1):179-187.
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
• Dokuzeylül Güngör N, Gürbüz T. Prediction of the number of oocytes based on AMH and FSH levels in IVF candidates. J Surg Med. 2020; 4(9):733-737.
• Jun TJ, Jelani AM, Omar J, Rahim RA, Yaacob NM. Serum anti-Müllerian hormone in polycystic ovary syndrome and its relationship with insulin resistance, lipid profile and adiponectin. Indian J Endocrinol Metab. 2020;24(2):191-195.
• Li XJ, Wang H, Lu DY, et al. Anti-Müllerian hormone accelerates pathological process of insulin resistance in polycystic ovary syndrome patients. Horm Metab Res. 2021;53(8):504-511.
• Gurbuz T, Gungor ND. Understanding the effects of obesity over polycystic ovary syndrome by analyzing insulin resistance and thyroid hormone in different BMI levels. Ulutas Med J. 2021;7(1):8-12. 
• Niepsuj J, Franik G, Madej P, Piwowar A, Bizoń A. Evaluation of pro/antioxidant imbalance in blood of women with polycystic ovary syndrome based on determination of oxidized low-density lipoproteins and ferric reducing ability of plasma values. Biomedicines. 2022;10(7):1564.
• Niu J, Lu M, Liu B. Association between insulin resistance and abnormal menstrual cycle in Chinese patients with polycystic ovary syndrome. J Ovarian Res. 2023;16(1):45.
• Oueslati I, Hammami MB, Boukriba S, et al. Anti Mullerian hormone as a diagnostic tool for polycystic ovary syndrome in women of reproductive age with morbid obesity. Horm Mol Biol Clin Investig. 2022;43(4):381-387.
• Ran Y, Yi Q, Li C. The relationship of anti-mullerian hormone in polycystic ovary syndrome patients with different subgroups. Diabetes Metab Syndr Obes. 2021;14:1419-1424.
• Ozay AC, Emekcı Ozay O, Gulekli B. Comparison of anti-Müllerian hormone (AMH) and hormonal assays for phenotypic classification of polycystic ovary syndrome. Ginekol Pol. 2020;91(11):661-667.
• Pérez-López FR, Ornat L, López-Baena MT, Santabárbara J, Savirón-Cornudella R, Pérez-Roncero GR. Circulating kisspeptin and anti-Müllerian hormone levels, and insulin resistance in women with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression. Eur J Obstet Gynecol Reprod Biol. 2021;260:85-98.
• Mitra S, Saharia GK, Jena SK. Cardio-metabolic risk in Rotterdam clinical phenotypes of PCOS. Ann Endocrinol (Paris). 2023;S0003-4266(23)00113-0.
• Rios JS, Greenwood EA, Pavone MEG, et al. Associations between anti-mullerian hormone and cardiometabolic health in reproductive age women are explained by body mass index. J Clin Endocrinol Metab. 2020;105(1):e555-e563.
• Shi X, Peng D, Liu Y, Miao X, Ye H, Zhang J. Advantages of serum anti-Müllerian hormone as a marker for polycystic ovarian syndrome. Lab Med. 2019;50(3):236-242.
• Su N, Zhan J, Xie M, et al. High anti-Mullerian hormone level is adversely associated with cumulative live birth rates of two embryo transfers after the first initiated cycle in patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2023;14:1123125.
• van Helden J, Evliyaoglu O, Küberl A, Weiskirchen R. Disorders of the glucose metabolism correlate with the phenotype and the severity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2020;93(1):44-51.
• Zhao H, Zhou D, Liu C, Zhang L. The relationship between insulin resistance and obesity and serum anti-mullerian hormone level in chinese women with polycystic ovary syndrome: a retrospective, single-center cohort study. Int J Womens Health. 2023;15:151-166.